Filing Flows › Veracyte (VCYT) › Q3 2026 › vs Q2 2026
Veracyte (VCYT) Q3 2026 vs Q2 2026 (quarter over quarter)
Veracyte's revenue rose $1.4M (+1%) from $150M in Q2 2026 to $152M in Q3 2026. The biggest changes: Product revenue +$768K (+20%); Testing revenue +$758K (+0.5%); Biopharmaceutical and other revenue −$93K (-12%). Gross margin 70.6% against 72.2% (-1.6 pts).
Veracyte, Q3 2026: revenue $152M (+15% year over year), operating margin 10.9%, net earnings $31.5M, operating cash flow $40.3M. The chart draws each line against Q2 2026, the increases inside each band.
Margins
| Q3 2026 | Q2 2026 | Change | |
|---|---|---|---|
| Gross margin | 70.6% | 72.2% | -1.6 pts |
| Operating margin | 10.9% | 15.3% | -4.4 pts |
| Net margin | 20.8% | 17.0% | +3.8 pts |
| Free cash flow margin | 25.0% | 28.6% | -3.6 pts |
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Testing revenue | $146M | $146M | $758K | +0.5% |
| Product revenue | $4.6M | $3.9M | $768K | +20% |
| Biopharmaceutical and other revenue | $709K | $802K | −$93K | -12% |
| Revenue | $152M | $150M | $1.4M | +1% |
| Gross profit | $107M | $109M | −$1.4M | -1% |
| Cost of revenue | $44.6M | $41.8M | $2.9M | +7% |
| Other income, net | $4.6M | $3.5M | $1.0M | +29% |
| Operating profit | $16.6M | $23.0M | −$6.4M | -28% |
| Operating expenses | $90.5M | $85.6M | $5.0M | +6% |
| Pre-tax earnings | $21.1M | $26.5M | −$5.4M | -20% |
| Research & development | $32.2M | $29.4M | $2.7M | +9% |
| Sales & marketing | $28.7M | $28.3M | $389K | +1% |
| General & admin | $29.3M | $27.4M | $1.9M | +7% |
| Other operating costs | $422K | $421K | $1K | +0.2% |
| Income tax benefit | $10.4M | −$1.0M | $11.4M | — |
| Net earnings | $31.5M | $25.5M | $6.0M | +24% |
| Depreciation & amortization | $6.0M | $4.8M | $1.1M | +24% |
| Share-based compensation | $14.0M | $14.1M | −$127K | -0.9% |
| Working capital & other | $11.2M | −$1.4M | $12.6M | — |
| Operating cash flow | $40.3M | $45.8M | −$5.6M | -12% |
| Free cash flow (OCF − capex) | $37.9M | $43.0M | −$5.0M | -12% |
| Capital expenditures | $2.3M | $2.9M | −$525K | -18% |
Questions
How much did Veracyte's revenue grow quarter over quarter in Q3 2026?
Veracyte's revenue rose $1.4M (+1%) from $150M in Q2 2026 to $152M in Q3 2026.
What drove Veracyte's revenue change in Q3 2026?
Product revenue +$768K (+20%); Testing revenue +$758K (+0.5%); Biopharmaceutical and other revenue −$93K (-12%).